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Plain English summary  9 
In 2014 Parkinson’s UK asked people with Parkinson’s, their carers and healthcare professionals 10 
working in Parkinson’s, collectively known as stakeholders, to identify aspects of Parkinson’s that 11 
urgently needed to be researched to identify new treatments or management strategies. A range of 12 
non-motor symptoms of Parkinson’s were ranked as important including: sleep quality, stress and 13 
anxiety, mild cognitive impairment, dementia and urinary problems. The purpose of this exercise was 14 
to build on the work of Parkinson’s UK by asking a group of stakeholders to identify and prioritise non-15 
drug treatments which should be researched as potential treatments for these non-motor symptoms.  16 
This Patient and Public Involvement Exercise used some Delphi techniques to reach agreement on 17 
which treatments should be prioritised. This consisted of a survey, followed by panel discussion and a 18 
post panel survey. Nine people with Parkinson’s and 10 healthcare professionals completed the first 19 
round survey, 8 people with Parkinson’s and 8 healthcare professionals participated in the panel 20 
discussion and 13 people with Parkinson’s completed the second round survey. There was good 21 
agreement on research priorities between people with Parkinson’s and Healthcare professionals. 22 
Physical exercise, talking therapies and cognitive training were identified as treatments which had 23 
shown some promising improvements in relevant symptoms, were acceptable to people with 24 
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Parkinson’s and were practical to carry out and therefore should be the focus of research. There was 25 
agreement that treatments which had the potential to improve multiple symptoms such as talking 26 
therapies should be prioritised. The exercise provides a comprehensive list of practical and acceptable 27 
non-drug treatments for non-motor symptoms of Parkinson’s which can be used to push forward 28 
research to improve the lives of people with Parkinson’s and their families. 29 
Abstract  30 
Background: In 2014 Parkinson’s UK conducted a research prioritisation exercise with stakeholders 31 
highlighting important clinical research questions. The exercise highlighted the need for effective 32 
interventions to be developed and tested to tackle a range of non-motor symptoms including: sleep 33 
quality, stress and anxiety, mild cognitive impairment, dementia and urinary problems. The present 34 
work set out to build on this exercise by prioritising types of non-pharmacological interventions to be 35 
tested to treat the identified non-motor symptoms.  36 
Methods: A Patient and Public Involvement Exercise was used to reach consensus on intervention 37 
priorities for the treatment on non-motor symptoms. Some Delphi techniques were also used to 38 
support the feedback collected. A first-round prioritisation survey was conducted followed by a panel 39 
discussion. Nineteen panellists completed the first-round survey (9 people with Parkinson’s and 10 40 
professionals working in Parkinson’s) and 16 participated in the panel discussion (8 people with 41 
Parkinson’s and 8 professionals working in Parkinson’s). A second-round prioritization survey was 42 
conducted after the panel discussion with 13 people with Parkinson’s.   43 
Results: Physical activity, third wave cognitive therapies and cognitive training were rated as priority 44 
interventions for the treatment of a range of non-motor symptoms. There was broad agreement on 45 
intervention priorities between health care professionals and people with Parkinson’s.  A consensus 46 
was reached that research should focus on therapies which could be used to treat several different 47 
non-motor symptoms.  In the context of increasing digitisation, the need for human interaction as an 48 
intervention component was highlighted.   49 
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Conclusion: Bringing together Parkinson’s professionals and people with Parkinson’s resulted in a final 50 
treatment priority list which should be both feasible to carry out in routine clinical practice and 51 
acceptable to both professionals and people with Parkinson’s. The workshop further specified 52 
research priorities in Parkinson’s disease based on the current evidence base, stakeholder 53 
preferences, and feasibility. Research should focus on developing and testing non-pharmacological 54 
treatments which could be effective across a range of symptoms but specifically focusing on tailored 55 
physical activity interventions, cognitive therapies and cognitive training.    56 
 57 
 58 
Keywords: Parkinson’s disease, research prioritisation, public and patient involvement, research 59 
engagement, intervention development, self-management 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
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Background 69 
In 2014 Parkinson’s UK conducted a priority setting exercise to identify research questions that key 70 
stakeholders, people with Parkinson’s and clinicians, wanted to prioritise (1). The exercise highlighted 71 
the need to identify and test effective treatments for a range of non-motor symptoms of Parkinson’s 72 
disease (PD) including stress and anxiety, dementia, mild thinking and memory problems, sleep and 73 
urinary problems. The present work further developed this by asking stakeholders to prioritise 74 
potential treatment types for the non-motor symptoms highlighted in the 2014 exercise.  75 
 76 
PD is considered to be a movement disorder defined by the presence of motor symptoms, such as 77 
bradykinesia, tremor and rigidity. It is now, however, widely accepted that PD is characterised not only 78 
by its motor aspects, but also by numerous non-motor symptoms that encompass sensory 79 
abnormalities, behavioural changes, sleep disturbances, autonomic dysfunction, and fatigue. In two 80 
recent studies, at least one non-motor symptom was reported by almost 100% of patients (2). The 81 
non-motor symptoms of PD can be as disabling for an individual as their motor symptoms, if not more 82 
so (3). Indeed, non-motor symptoms dominate the clinical picture of PD and contribute to severe 83 
disability, impaired quality of life, and shortened life expectancy (4, 5).  84 
 85 
There is currently limited evidence for effective treatments for non-motor symptoms (6, 7), either 86 
pharmacological or non-pharmacological. Consequently, even when non-motor symptoms are 87 
recognised in a clinical consultation, treatment rates remain low as evidenced in recent reports (8, 9).     88 
 89 
The failure to treat non-motor symptoms due to the lack of effective pharmacological treatments is 90 
especially true in the case of fatigue, anxiety and depression in PD. People with PD benefit less from 91 
antidepressant treatment, than do people without PD (10). Also, there is a high risk of adverse side 92 
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effects and adverse interactions between antidepressants and antiparkinsonian medications (11). 93 
Benzodiazepines, used commonly for anxiety disorder treatment, are not recommended for people 94 
living with PD due to adverse effects including cognitive and psychomotor impairment (12) and 95 
increased risk of falls (13). Atomoxetine, was not found to be efficacious for anxiety in PD (14). 96 
Currently insufficient evidence exists to support the treatment of fatigue in PD with any drug or non-97 
pharmacological treatment, highlighting the need for further research (15). Furthermore, there is 98 
often a reluctance by many PD patients to take additional medication or change finely balanced 99 
medication regimes for motor symptoms in order to treat non-motor symptoms (16).  100 
For non-motor symptoms where pharmacological treatments lack effectiveness, there is a growing 101 
evidence base showing that non-pharmacological treatments might be able to help. Cognitive 102 
Behavioural Therapy (CBT), including distance delivered CBT, has moderate effects on improving 103 
anxiety and depression, insomnia and impulse-control disorders in PD (17, 18). Emerging evidence has 104 
suggested that mindfulness-based interventions can help reduce symptoms of depression (19-21), and 105 
symptoms of anxiety (19, 21).  Consequently the present exercise sought to prioritize non-106 
pharmacological treatments for a range of non-motor symptoms idenitfied as priorities in the 2014 107 
exercise, namely: stress and anxiety, dementia, mild thinking and memory problems, sleep and urinary 108 
problems.  109 
110 
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Methods 111 
 112 
Structure 113 
From the outset of this Patient and Public Involvement Exercise (PPIE) we decided to adopt elements 114 
of the Delphi technique to guide the development of consensus. The purpose of the meeting was to 115 
bring together relevant stakeholders to identify and prioritise psychological and behavioural 116 
interventions which may improve non-motor symptoms. Using guidance from the Delphi technique 117 
helped us to collect stakeholders’ feedback in a more systematic way. The Delphi technique is an 118 
iterative questionnaire exercise with controlled feedback to a group of panellists (22). The ‘panellists’ 119 
are purposively selected for their particular expertise on a topic and the questionnaire exercise is often 120 
conducted across a series of two or more sequential ‘rounds’. In the current prioritisation exercise, 121 
two rounds of questionnaires were used; one before and one following the panel discussion. The 122 
structure of the process is outlined in figure 1. Patient and Public Involvement (PPI) was central to the 123 
process as demonstrated in the Guidance for Reporting Involvement of Patients and the Public (GRIPP) 124 
2- short form checklist (24) in table 1. 125 
We brought together a range of key stakeholders: people with Parkinson’s, psychological and 126 
behavioural researchers specialising in Parkinson’s, and healthcare professionals working in 127 
Parkinson’s. Bringing together all interested parties in a single day meeting allowed dialogue between 128 
individuals and the sharing of perspectives to ensure that decisions regarding the final research 129 
priorities were collaborative. 130 
 131 
Stage 1: Identifying experts for the exercise ‘The panel’ 132 
Turoff  (25) recommends panels between 10 and 50.  Ten people with Parkinson’s and ten health 133 
professionals (geriatrician, psychologists, PD nurses, physiotherapist, occupational therapist, speech 134 
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therapist) initially agreed to take part in the exercise. The health professionals, whose expertise was 135 
based on qualifications and proven track records in the field, were identified through peer 136 
consultation and invited via email by the authors. People with Parkinson’s and carers were invited by 137 
Parkinson’s UK through an email to their Research Network mailing list.   138 
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Figure 1. Delphi Flow chart 139 
 140 
 141 
 142 
 143 
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 149 
 150 
 151 
 152 
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 156 
 157 
 158 
PwP = People with Parkinson’s 159 
 160 
 161 
Stage 1: Identify experts to participate in the 
exercise: 10 PWP and 10 Health Professionals 
Stage 2: Generate list of non-pharmacological 
interventions 
Stage 5: 2nd round questionnaires 
1st round questionnaire refined by removing low priority and unacceptable/unfeasible 
interventions and additional interventions added 
Prioritising importance of consensus list of interventions 
Completed online by 13 PwP 
Stage 4: Panel discussion 
8 PwP and 8 Health Professionals participated Discussion of feasibility and acceptability of 
suggested interventions 
Generation of new interventions 
Reaching consensus on interventions for prioritization for each symptom 
Stage 3: 1st round questionnaire 
Prioritising the importance of interventions for each symptom 
Online survey completed by 9 PwP and 10 Health Professionals  
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Table 1 here 162 
 163 
Stage 2: Generate list of non-pharmacological interventions 164 
The initial list of non-pharmacological interventions for the first round questionnaire was developed 165 
from literature reviews in PD and similar conditions conducted by two authors (AB and LR) who 166 
specialise in behavioural interventions in PD. Due to resource constraints the panellists were not 167 
consulted in this initial idea generation phase for salient non-pharmacological interventions to include 168 
in the survey.  169 
Stage 3: Survey round 1 170 
The survey rounds were completed using the online tool Survey Monkey (26).  The survey asked 171 
panellists to rank the importance of each suggested non-pharmacological intervention for each of the 172 
non-motor symptoms identified as research priorities in the Parkinson’s UK prioritization exercise: 173 
stress and anxiety, dementia, mild thinking and memory problems, sleep and urinary problems) (1). A 174 
short explanation of each intervention was provided for clarity. Panellists were asked to rank the 175 
interventions into order of treatment priority with 1 = highest treatment priority using a drop-down 176 
menu. Respondents were then instructed to keep assigning numbers to each treatment until they 177 
were sure that the treatment would not help for the symptom. Unhelpful treatments were not 178 
assigned a number in the ranking. A screen shot of the treatment ranking exercise is shown in figure 179 
2. 180 
 181 
 182 
 183 
 184 
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 185 
Figure 2. Treatment Priority Ranking in the Round One Survey 186 
 187 
 188 
Stage 4: The panel discussion in-between survey rounds 189 
The panel discussion was facilitated by the first and second author. All members of the panel were 190 
made aware of the background of the two facilitators, i.e. health psychology researchers in the area 191 
of non-pharmacological treatments in PD and were also made aware of their interest, i.e. identify 192 
research priorities for future research grant applications. Respondents were aware of the topic of the 193 
discussion and had already taken part in the survey that the discussion was based on. No other 194 
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preparation was required prior to the meeting.  The panel discussion included eight people with 195 
Parkinson’s disease, and eight health professionals. The discussion started with a short presentation 196 
on the most prevalent non-motor symptoms, followed by our suggestions for non-pharmacological 197 
interventions, followed by the ranking results of the first-round survey. The non-motor symptom 198 
priorities focused on during the workshop were: stress and anxiety, dementia, mild cognitive 199 
problems, quality of sleep, urinary problems. For each of these categories, respondents were asked 200 
to discuss: 201 
-What behavioural and psychological management interventions are available? 202 
-What is the research evidence and your personal experience with management of these non-motor 203 
symptoms? 204 
-Which behavioural and psychological management interventions do you consider as the highest 205 
priorities? 206 
The group discussed preferences in terms of types of psychological and behavioural interventions for 207 
non-motor symptoms in Parkinson’s, as well as the mode of delivery, that best suits people with 208 
Parkinson’s and how likely these interventions were to be translated into clinical practice. Current 209 
clinical practices in Parkinson’s were also discussed and how potential interventions on specific non-210 
motor symptoms could be added to current common practice.  211 
The group then prioritised interventions for research based on potential intervention efficacy, 212 
acceptability, need and translation into clinical practice. After discussing specific treatments, the 213 
facilitators asked the group which non-pharmacological intervention they consider the most 214 
important and promising. One of the panelists kept notes on a white board as people offered 215 
suggestions and thoughts. This discussion largely focused on one specific intervention and the 216 
facilitators summarised and confirmed with the group that this intervention should be prioritised. 217 
 218 
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 220 
Stage 5: Survey round 2 221 
Following the panel discussion, the first-round survey was refined by adding interventions not 222 
previously included and narrowing down the available intervention options for each non-motor 223 
symptom. We removed interventions with very low rankings at the first survey or interventions that 224 
were not considered appropriate based on the panel discussion. For example, we added ‘peer group 225 
support’ under ‘anxiety’ and removed ‘acceptance and commitment therapy’ under ‘sleep’. A 226 
question about mode of delivery preferences was also added. 227 
For the second-round survey we asked the panel to re-rate the interventions suggested for each non-228 
motor symptom and emailed the survey to Parkinson’s UK Research Network members. Thirteen 229 
people with Parkinson’s responded to the survey, two of whom had attended the workshop.  230 
 231 
Ethics 232 
The goal of the project was to gather information to direct future research using Public and Patient 233 
Involvement. According to NIHR INVOLVE guidelines ethical approval is not needed when the public 234 
acts as specialist advisors, providing expertise based on their experience of a health condition in 235 
planning or advising on research. Prior published research priority setting exercises have also 236 
suggested that ethical approval is not required (1). It was assumed that the ability to complete the 237 
online surveys suggested that the respondents had capacity to consent in the exercise.  No 238 
incentives were offered to respondents but all travel expenses were reimbursed.  239 
 240 
  241 
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Results 242 
Intervention Ranking 243 
The results of the first-round survey showed that physical activity, stress-management and cognitive 244 
training were high priorities for a variety of non-motor symptoms. More details on the top three 245 
behavioural interventions for each non-motor symptom are presented in table 2. Physical activity, 246 
cognitive training and third wave therapies including cognitive behaviour therapy and mindfulness 247 
were all ranked as high priorities in the second-round survey. 248 
 249 
Table 2 here 250 
 251 
During the panel discussion additional behavioural interventions were discussed, such as peer support 252 
groups to manage stress and anxiety; on-going assessments and care for dementia, pelvic floor 253 
exercises as part of self-management for urinary problems and massage and the use of a light box to 254 
help manage sleep. These non-pharmacological interventions were added in the post-panel survey, 255 
but they were not identified as a priority (table 2). Table 3 summarizes the number of interventions 256 
that were added and removed at each stage of the process.  257 
  258 
14 
 
Table 3. Number of non-pharmacological interventions in advance of, during and after the panel 259 
discussion 260 
Key non-motor 
symptoms 
Total number of 
interventions 
generated at pre-
discussion survey 
Number of 
interventions 
remaining 
following panel 
discussion 
Additional 
interventions 
generated during 
discussion 
Final number of 
interventions for 
ranking 
Stress and anxiety 14 7 1 8 
Dementia 17 5 1 6 
Mild thinking and 
memory problems 
17 7 0 7 
Quality of sleep 17 5 2 7 
Urinary problems 4 0 0 4 
 261 
 262 
As shown in table 2, the three highest ranked interventions for each non-motor symptom did not 263 
change significantly between the first and second survey rounds. Ten HCPs and 10 people with 264 
Parkinson’s responded to the first-round survey and 13 people with Parkinson’s responded to the 265 
second-round survey. Table 4 shows the first-round survey responses divided by respondent type 266 
(professional vs person with Parkinson’s). There was broad agreement on intervention priorities 267 
across respondent group. 268 
  269 
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Table 4. First round survey priorities by respondent type  270 
Key non-motor 
symptoms 
Professionals top three 
interventions 
People with Parkinson’s top three 
interventions 
Stress and anxiety 1. Cognitive behavior 
therapy 
2. Mindfulness 
3. Stress management 
1. Cognitive behavior therapy 
2. Stress management 
3. Mindfulness 
Dementia 1. Cognitive skills training 
2. Lifestyle management 
strategies 
3. Carer support 
1. Cognitive skills training 
2. Carer support 
3. Compassion focused 
therapy 
Mild thinking and 
memory problems 
1. Cognitive skills training 
2. Acceptance and 
commitment therapy 
3. Stress management 
1. Cognitive skills training 
2. Cognitive behavior therapy 
3. Physical activity 
Quality of sleep 1. Sleep hygiene 
2. Cognitive behavior 
therapy 
3. Self-management  
1. Physical activity 
2. Sleep hygiene 
3. Mindfulness 
Urinary problems 1. Self-management 
2. Lifestyle management 
3. Carer support 
1. Self-management 
2. Lifestyle management 
3. Carer support 
 271 
 272 
  273 
16 
 
Mode of delivery  274 
In the second-round survey a question was added exploring preferences for mode of delivery of non-275 
pharmacological interventions.  Of the 13 PD respondents, eight preferred individual face-to-face 276 
delivery of interventions, four preferred online delivery with some peer or professional contact, and 277 
one wanted group support or group therapy. 278 
 279 
Outcomes from the panel discussion 280 
There was consensus that physical exercise is beneficial in PD but there is limited knowledge on PD 281 
specific exercises. There was also a consensus that ideally, we need an intervention that will cover 282 
more than one symptom.  For example, talking therapies could be applied to more than one non-283 
motor symptom at a time, such as anxiety, depression, and sleep problems, and augment other 284 
treatment approaches, such as facilitating adherence to exercise, pacing activities of daily living and 285 
self-management.  286 
People with Parkinson’s emphasised the need for personalised treatments.  They were aware that one 287 
size did not fit all and that the same symptoms can impact people differently, so they needed to be 288 
cautious when suggesting one treatment for one symptom in all cases. In order to get the maximum 289 
potential benefit from treatments delegates agreed that treatments need to be tailored to the 290 
individual.  291 
With the increasing use of digital technologies to deliver interventions the panel reached a consensus 292 
that face to face contact in intervention delivery remained of central importance as a method of 293 
combating social isolation.  294 
 295 
 296 
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Discussion 297 
This exercise extended the priority setting work conducted by Parkinson’s UK (4) with a focus on 298 
prioritising non-pharmacological treatments to tackle the non-motor symptoms highlighted by the 299 
Parkinson’s UK exercise namely: sleep quality, dementia, mild memory problems, stress and anxiety 300 
and urinary problems.  301 
There was good consensus on treatment priorities between Parkinson’s professionals and people with 302 
Parkinson’s. Many overlapping interventions were identified for different symptoms for example 303 
physical activity, cognitive skills training and mindfulness. While both people with PD and healthcare 304 
professionals generally ranked physical activity as a priority it was evident that there was a lack of 305 
clarity around which physical exercises were recommended for people with Parkinson’s. Research to 306 
date has shown physical exercise to have beneficial effects on a range of non-motor symptoms (27). 307 
Future research should focus on providing evidence-based guidance for physical activity in PD that can 308 
be easily implemented by clinicians and patients. 309 
Similarly, there is accumulating evidence for the efficacy of cognitive skills training in PD (28) but there 310 
is large methodological variability between studies and a limited understanding of the long-term 311 
efficacy of this approach. Future research should seek to conduct larger, controlled studies which aim 312 
to determine which patient groups may benefit most from cognitive skills training (28) enabling 313 
targeted provision for those who will benefit most. 314 
The efficacy of third wave therapies such as mindfulness, cognitive behaviour therapy and stress 315 
management is increasingly being tested for a range of non-motor symptoms in PD (19-21, 29-31) with 316 
some positive preliminary results. Large, controlled trials with longer follow up periods are needed.  317 
A challenge of providing these interventions is often one of resource, particularly when a trained 318 
therapist is required to implement an intervention. Despite the recent proliferation of online 319 
interventions in Parkinson’s (29, 30, 32) which have clear practical benefits, there was a consensus 320 
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that an element of face-to-face contact was required in intervention delivery. It is essential to carefully 321 
balance the preferences of people with Parkinson’s with the practicalities of delivering cost-effective 322 
interventions to large groups. Consequently, finding innovative ways to implement the intervention 323 
whilst still maintaining human contact, rather than taking a purely digital approach, is paramount. 324 
Recent work exploring the use of skype conferencing to deliver mindfulness interventions (29, 33) or 325 
the use of lay facilitators to deliver interventions across conditions may be important avenues for 326 
further research (34-36).  327 
It was evident from the panel discussion that rather than treatments tailored to symptoms, people 328 
with Parkinson’s and professionals working in the area of Parkinson’s wanted global interventions 329 
which might have positive effects across a range of symptoms. Future research should endeavour to 330 
explore the use of therapies such as CBT and mindfulness to support self-management of other non-331 
motor symptoms e.g. urinary symptoms and cognitive symptoms.  332 
Bringing together Parkinson’s professionals and people with Parkinson’s allowed both parties view’s 333 
to be heard, combining feasibility of delivering an intervention with patient and carer preferences. 334 
Asking stakeholders to produce a consensus list of priority interventions helps ensure that the 335 
research agenda moves forward and research into identified interventions is undertaken as 336 
stakeholders are engaged with the research process. The final treatment priority list should be both 337 
feasible to carry out in routine clinical practice and acceptable to both professionals and people with 338 
Parkinson’s increasing the likelihood of implementation of effective interventions in the NHS. 339 
Furthermore, the bringing together of clinicians, researchers and people with PD provides strategic 340 
alliances facilitating future research programmes.   341 
This priority setting exercise was not without limitations. The largest of these being the difference in 342 
respondents completing the survey pre and post the panel discussion. The first-round survey was 50% 343 
people with Parkinson’s and 50% professionals, the majority of whom then attended the panel 344 
discussion. However, the second-round survey was solely completed by people with Parkinson’s, only 345 
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a small proportion of whom attended the discussion. Possible reasons for the lack of engagement in 346 
the second-round survey could include the realities of a busy schedule or panellists may have felt that 347 
they had ‘already had their voice heard’. This latter point may have been more salient in the present 348 
exercise as relatively few changes were made to the intervention list as a consequence of the panel 349 
discussion. Therefore respondents may have felt the process had an element of repetition.  350 
It is possible that the interventions prioritized in the second-round survey only reflect the views of 351 
people with Parkinson’s as no professionals completed this round. However, the concordance in 352 
priority setting seen between professionals and people with Parkinson’s in the first-round survey 353 
suggests that the second-round survey results may have been relatively similar had it also been 354 
completed by Parkinson’s professionals. Conversely the inclusion of a largely new group of 355 
respondents in the second-round survey provides support for the generalisability of the findings in the 356 
first round of the survey. Treatment priorities showed little variation pre and post panel discussion.  357 
Conclusions 358 
In summary, the present exercise further specifies research priorities in Parkinson’s disease based on 359 
the current evidence base, stakeholder preferences, and feasibility. Research should focus on 360 
developing and testing non-pharmacological treatments which could be effective across a range of 361 
non-motor symptoms but specifically focusing on tailored physical activity interventions, cognitive 362 
skills training and psychological therapies including mindfulness, cognitive behavioural therapy and 363 
stress management.    364 
 365 
 366 
 367 
  368 
20 
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Table 1 PPI in the non-pharmacological treatment prioritisation exercise using GRIPP2-SF 489 
Section and Topic Item 
1. Aim 
Report the aim of the study 
To collaboratively involve patients in the 
prioritization of non-pharmacological treatment 
types for the management of non-motor 
symptoms. 
2. Methods 
Provide a clear description of the 
methods used for PPI in the study 
10 patient partners were recruited as panelists 
for the prioritization exercise. They were 
involved in discussions refining the intervention 
prioritization list, took part in the consensus 
workshop and the intervention prioritization 
exercise. A further 11 patient partners were 
involved in the 2nd round intervention 
prioritization exercise. 
3. Results 
Outcomes – report the results of PPI in 
the study, including both positive and 
negative outcomes 
PPI contributed to the study in several ways 
including: 
Providing patient experience and perspectives 
to inform discussions to refine the intervention 
prioritization list. Prioritized non-
pharmacological intervention types for a range 
of non-motor symptoms in the first and second 
round surveys to provide a definitive list of 
research priorities.   
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4. Discussion 
Outcomes – comment on the extent to 
which PPI influenced the study overall.  
Patient involvement in this process was highly 
influential. Using the experience and 
understanding the preferences of patients was 
central to the prioritization exercise which was 
intended to be a collaboration between 
stakeholders.  The final list of research priorities 
was strongly influenced by patient involvement. 
5. Reflections PPI was embedded into the exercise from the 
outset and PPI panelists were able to 
meaningfully engage in the prioritization 
exercise. The small number of patients from 
round 1 and the panel discussion retained at 
round 2 is a limitation. In future exercises 
safeguards will be put in place in an attempt to 
minimize attrition such as scheduling survey 
completion times and following up non-
responders.    
 490 
 491 
 492 
 493 
 494 
 495 
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Table 2. Top three non-pharmacological interventions identified for each non-motor symptom in 
the first and second round surveys 
Non-
motor 
sympto
m 
Interventions (1st round 
survey) 
Panel discussion 
(consensus following 
discussion of efficacy, 
acceptability and need) 
Interventions (2nd round 
survey) 
Stress 
and 
anxiety 
1. Cognitive 
behavioural 
therapy (talking 
therapy that can 
help you manage 
your problems by 
changing the way 
you think and 
behave) 
2. Stress 
management 
(techniques aimed 
at controlling a 
person’s levels of 
stress) 
3. Mindfulness  
1. Acceptance and 
commitment 
therapy 
(acceptance and 
committing to 
valued actions) 
2. Mindfulness  
3. Cognitive 
behavioural 
therapy (talking 
therapy that can 
help you manage 
your problems by 
changing the way 
you think and 
behave) 
1. Physical activity 
(personalised 
physical activity) 
2. Cognitive 
behavioural 
therapy (talking 
therapy that can 
help you manage 
your problems by 
changing the way 
you think and 
behave) 
3. Mindfulness 
 
Dementi
a 
1. Cognitive skills 
training 
(compensatory 
1. Screening 
programme to 
4. Lifestyle 
management 
strategies 
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cognitive skills 
from 
neurorehabilitatio
n) 
2. Caregiver support 
(teaching 
caregivers skills to 
identify problems 
and support 
people with 
Parkinson’s) 
3. Lifestyle 
management 
strategies 
detect /monitor 
cognitive changes.  
2. Cognitive skills 
training 
(compensatory 
cognitive skills 
from 
neurorehabilitatio
n) 
3. Caregiver support 
(teaching 
caregivers skills to 
identify problems 
and support 
people with 
Parkinson’s) 
5. Caregiver support 
(teaching 
caregivers skills to 
identify problems 
and support 
people with 
Parkinson’s) 
6. Cognitive skills 
training 
(compensatory 
cognitive skills 
from 
neurorehabilitatio
n) 
 
Mild 
thinking 
and 
memory 
problem
s 
1. Cognitive skills 
training 
(compensatory 
cognitive skills 
from 
neurorehabilitatio
n) 
2. Stress 
management 
1. Screening 
programme to 
detect /monitor 
cognitive changes.  
2. Cognitive skills 
training 
(compensatory 
cognitive skills 
from 
1. Physical activity 
(personalised 
physical activity 
treatment) 
2. Cognitive skills 
training 
(compensatory 
cognitive skills 
from 
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(techniques aimed 
at controlling a 
person’s levels of 
stress) 
3. Physical activity 
(personalised 
physical activity 
treatment) 
neurorehabilitatio
n) 
Caregiver support 
(teaching 
caregivers skills to 
identify problems 
and support 
people with 
Parkinson’s) 
neurorehabilitatio
n) 
3. Stress 
management 
(techniques aimed 
at controlling a 
person’s levels of 
stress) 
 
Quality 
of sleep 
1. Sleep hygiene 
2. Physical activity 
(personalised 
physical activity 
treatment) 
3. Mindfulness  
1. Sleep hygiene 
2. Technology 
Enabled care (to 
monitor sleep, but 
also falls and 
nocturia at night) 
 
1. Sleep hygiene 
2. Physical activity 
(personalized 
physical activity 
treatment) 
3. Mindfulness 
Urinary 
problem
s 
1. Self-management 
for urinary 
problems (fluid 
management, 
caffeine and 
alcohol 
management, 
bladder retraining) 
1. Self-management 
for urinary 
problems (fluid 
management, 
caffeine and 
alcohol 
management, 
bladder retraining) 
 
1. Self-management 
for urinary 
problems (fluid 
management, 
caffeine and 
alcohol 
management, 
bladder retraining) 
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2. Lifestyle 
management 
strategies 
3. Technology 
Enabled care 
2. Lifestyle 
management 
strategies 
3. Technology 
Enabled care 
§ = includes physiotherapy and rehabilitation §§ = exercise classes and program 
 
 
 
